vs
Side-by-side financial comparison of Atara Biotherapeutics, Inc. (ATRA) and Palladyne AI Corp. (PDYN). Click either name above to swap in a different company.
Palladyne AI Corp. is the larger business by last-quarter revenue ($1.7M vs $1.6M, roughly 1.0× Atara Biotherapeutics, Inc.). On growth, Palladyne AI Corp. posted the faster year-over-year revenue change (118.3% vs -95.1%). Over the past eight quarters, Palladyne AI Corp.'s revenue compounded faster (-30.5% CAGR vs -75.9%).
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
Palladyne AI Corp. is an American company known for most of its existence primarily as a developer of robots. Palladyne was founded in 1983 as Sarcos Research Corporation. In 2023, Sarcos shifted its business focus to the development of artificial intelligence (AI) software for robotic applications, discontinuing its hardware operations. In March 2024, the company changed its name to Palladyne AI.
ATRA vs PDYN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $1.7M |
| Net Profit | — | $-1.5M |
| Gross Margin | — | 15.6% |
| Operating Margin | — | -560.7% |
| Net Margin | — | -89.9% |
| Revenue YoY | -95.1% | 118.3% |
| Net Profit YoY | 73.2% | 97.2% |
| EPS (diluted) | — | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $1.7M | ||
| Q3 25 | $3.5M | $860.0K | ||
| Q2 25 | $17.6M | $1.0M | ||
| Q1 25 | $98.1M | $1.7M | ||
| Q4 24 | $32.8M | $761.0K | ||
| Q3 24 | $40.2M | $871.0K | ||
| Q2 24 | $28.6M | $2.7M | ||
| Q1 24 | $27.4M | $3.4M |
| Q4 25 | — | $-1.5M | ||
| Q3 25 | $-4.3M | $-3.7M | ||
| Q2 25 | $2.4M | $-7.5M | ||
| Q1 25 | $38.0M | $22.8M | ||
| Q4 24 | $-12.7M | — | ||
| Q3 24 | $-21.9M | $-7.1M | ||
| Q2 24 | $-19.0M | $-5.3M | ||
| Q1 24 | $-31.8M | $-7.2M |
| Q4 25 | — | 15.6% | ||
| Q3 25 | — | 46.4% | ||
| Q2 25 | — | 53.3% | ||
| Q1 25 | — | 79.4% | ||
| Q4 24 | — | 27.2% | ||
| Q3 24 | — | 45.0% | ||
| Q2 24 | — | 79.0% | ||
| Q1 24 | — | 45.2% |
| Q4 25 | — | -560.7% | ||
| Q3 25 | -103.5% | -937.8% | ||
| Q2 25 | 18.2% | -797.4% | ||
| Q1 25 | 39.5% | -405.3% | ||
| Q4 24 | -37.3% | — | ||
| Q3 24 | -54.1% | -838.0% | ||
| Q2 24 | -63.7% | -213.3% | ||
| Q1 24 | -114.2% | -213.7% |
| Q4 25 | — | -89.9% | ||
| Q3 25 | -124.6% | -434.9% | ||
| Q2 25 | 13.6% | -737.6% | ||
| Q1 25 | 38.7% | 1330.9% | ||
| Q4 24 | -38.8% | — | ||
| Q3 24 | -54.5% | -814.7% | ||
| Q2 24 | -66.5% | -196.2% | ||
| Q1 24 | -116.1% | -210.1% |
| Q4 25 | — | $-0.02 | ||
| Q3 25 | $-0.32 | $-0.09 | ||
| Q2 25 | $0.19 | $-0.20 | ||
| Q1 25 | $3.50 | $0.55 | ||
| Q4 24 | $0.27 | — | ||
| Q3 24 | $-2.93 | $-0.27 | ||
| Q2 24 | $-3.10 | $-0.20 | ||
| Q1 24 | $-5.65 | $-0.28 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $47.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-38.5M | $74.7M |
| Total Assets | $20.2M | $95.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $47.1M | ||
| Q3 25 | $13.7M | $57.1M | ||
| Q2 25 | $22.3M | $62.7M | ||
| Q1 25 | $13.8M | $46.6M | ||
| Q4 24 | $42.5M | $40.1M | ||
| Q3 24 | $67.2M | $21.3M | ||
| Q2 24 | $35.3M | $25.8M | ||
| Q1 24 | $46.2M | $31.8M |
| Q4 25 | $-38.5M | $74.7M | ||
| Q3 25 | $-36.6M | $51.8M | ||
| Q2 25 | $-35.0M | $53.8M | ||
| Q1 25 | $-55.1M | $28.3M | ||
| Q4 24 | $-97.3M | $-9.5M | ||
| Q3 24 | $-90.5M | $23.4M | ||
| Q2 24 | $-110.9M | $29.8M | ||
| Q1 24 | $-98.3M | $34.2M |
| Q4 25 | $20.2M | $95.7M | ||
| Q3 25 | $30.2M | $72.9M | ||
| Q2 25 | $36.9M | $78.3M | ||
| Q1 25 | $62.0M | $63.3M | ||
| Q4 24 | $109.1M | $56.3M | ||
| Q3 24 | $142.7M | $38.7M | ||
| Q2 24 | $117.3M | $45.1M | ||
| Q1 24 | $165.3M | $50.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.9M | $-8.5M |
| Free Cash FlowOCF − Capex | — | $-8.7M |
| FCF MarginFCF / Revenue | — | -526.2% |
| Capex IntensityCapex / Revenue | 0.0% | 14.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-50.9M | $-8.5M | ||
| Q3 25 | $-9.8M | $-6.3M | ||
| Q2 25 | $-7.3M | $-5.3M | ||
| Q1 25 | $-28.1M | $-7.5M | ||
| Q4 24 | $-24.5M | $-22.6M | ||
| Q3 24 | $-4.0M | $-4.5M | ||
| Q2 24 | $-10.6M | $-5.8M | ||
| Q1 24 | $-29.6M | $-7.2M |
| Q4 25 | — | $-8.7M | ||
| Q3 25 | — | $-6.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | $-24.6M | $-22.9M | ||
| Q3 24 | — | $-4.5M | ||
| Q2 24 | $-10.7M | $-5.9M | ||
| Q1 24 | $-29.7M | $-7.3M |
| Q4 25 | — | -526.2% | ||
| Q3 25 | — | -776.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -445.0% | ||
| Q4 24 | -75.0% | -3008.1% | ||
| Q3 24 | — | -517.8% | ||
| Q2 24 | -37.3% | -218.9% | ||
| Q1 24 | -108.7% | -212.1% |
| Q4 25 | 0.0% | 14.2% | ||
| Q3 25 | 0.0% | 44.7% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 5.4% | ||
| Q4 24 | 0.3% | 34.8% | ||
| Q3 24 | 0.0% | 1.4% | ||
| Q2 24 | 0.1% | 5.3% | ||
| Q1 24 | 0.5% | 1.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -3.07× | — | ||
| Q1 25 | -0.74× | -0.33× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
